Quantification of SMN protein and mRNA levels may be useful as a biomarker for SMA severity and to monitor the response to experimental strategies designed to increase SMN protein [11–14] and changes in SMN expression have already been used to study the potential of SMN-inducing drugs as a treatment for SMA [11, 14–19]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.